Country: Malta
Language: English
Source: Medicines Authority
FLUDARABINE PHOSPHATE
Accord Healthcare Limited
L01BB05
FLUDARABINE PHOSPHATE
CONCENTRATE FOR SOLUTION FOR INFUSION OR INJECTION
FLUDARABINE PHOSPHATE 25 mg/ml
POM
ANTINEOPLASTIC AGENTS
Authorised
2014-08-19
PACKAGE LEAFLET: INFORMATION FOR THE USER FLUDARABINE PHOSPHATE 25 MG/ML CONCENTRATE FOR SOLUTION FOR INJECTION OR INFUSION Fludarabine phosphate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, or pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours If you get any side effects, talk to your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4 WHAT IS IN THIS LEAFLET 1. What Fludarabine phosphate Injection is and what it is used for 2. What you need to know before you use Fludarabine phosphate Injection 3. How to use Fludarabine phosphate Injection 4. Possible side effects 5. How to store Fludarabine phosphate Injection 6. Contents of the pack and other information 1. WHAT FLUDARABINE PHOSPHATE INJECTION IS AND WHAT IT IS USED FOR WHAT FLUDARABINE PHOSPHATE INJECTION IS AND HOW IT WORKS: Fludarabine phosphate Injection contains the active substance Fludarabine phosphate. Pharmacotherapeutic group: Antineoplastic agents, purine analogues Fludarabine phosphate Injection is an intravenous injection or infusion that stops the growth of new cancer cells. All cells of the body produce new cells like themselves by dividing. Fludarabine phosphate Injection is taken up by the cancer cells and stops them dividing. In cancers of the white blood cells (such as chronic lymphocytic leukaemia), the body produces many abnormal white blood cells _(lymphocyt Read the complete document
Page 1 of 15 SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 25 mg fludarabine phosphate. 2 ml of solution contains 50 mg fludarabine phosphate. Excipient with known effect: Each mL contains <1 mmol sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for injection or infusion. Clear, colourless or slightly brownish-yellow solution, essentially free from particles. pH: 6.0 – 7.1 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of B-cell chronic lymphocytic leukaemia (CLL) in patients with sufficient bone marrow reserves. First line treatment with Fludarabine should only be initiated in patients with advanced disease, Rai stages III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) where the patient has disease related symptoms or evidence of progressive disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults _ The recommended dose is 25 mg fludarabine phosphate/m 2 body surface area given daily for 5 consecutive days every 28 days by intravenous route (See also section 6.6). The required dose (calculated on the basis of the patient's body surface) is drawn up into a syringe. For intravenous bolus injection this dose is further diluted in 10 ml sodium chloride 9 mg/ml (0.9%). Page 2 of 15 Alternatively, for infusion, the required dose may be diluted in 100 ml sodium chloride 9 mg/ml (0.9%) and infused over approximately 30 minutes. The o Read the complete document